Jazz Pharmaceuticals has signed a licencing agreement to acquire exclusive international rights to develop and market Werewolf Therapeutics’ investigational cancer therapy, WTX-613.

A differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE molecule, WTX-613 is presently in the preclinical stage.

This engineered IFN⍺2b cytokine pro-drug is activated within the tumour microenvironment to induce IFNα receptors on cancer-fighting immune effector cells. 

The goal of WTX-613 is to reduce the severe toxicities seen with systemically active recombinant IFNα therapy and enhance clinical benefit when given as a single agent or along with other agents. 

As per the deal, Werewolf is entitled to receive $15m upfront from Jazz.

Furthermore, Jazz will make development, regulatory and commercial milestone payments of up to $1.26bn to Werewolf. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

On obtaining approval for WTX-613, Werewolf is eligible for a tiered royalty payment on net product sales.

Adding WTX-613 will expand the oncology pipeline of Jazz and it is the first immuno-oncology programme in the company’s research and development portfolio.

Jazz also intends to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for WTX-613 next year.

In preclinical models, a surrogate WTX-613 INDUKINE molecule showed tumour stasis continuing beyond the treatment phase, effectively hindering tumour growth.

Jazz Pharmaceuticals research and development global head, executive vice-president Rob Iannone said: “We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumours, and thereby expanding its clinical utility in treating cancer. 

“This transaction underscores our commitment to enhancing our pipeline to deliver novel oncology therapies to patients, and also provides us with an opportunity to expand into immuno-oncology.” 

In August 2019, the company acquired US-based biotechnology firm Cavion for $312.5m.